Proteomics

Dataset Information

0

Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand


ABSTRACT: Canine cognitive dysfunction syndrome (CCDS) is a progressive neurodegenerative disorder found in senior dogs. Due to the lack of biological markers, CCDS is commonly underdiagnosed. The aim of this study was to identify potential plasma biomarkers using proteomics techniques and to increase our understanding of the pathogenic mechanism of the disease. Plasma amyloid beta 42 (Aβ42) has been seen to be a controversial biomarker for CCDS. Proteomics analysis was performed for protein identification and quantification. The nano-LC-MS/MS data revealed that the predictive underlying mechanism of CCDS was the co-occurrence of inflammation-mediated acute phase response proteins and complement and coagulation cascades that partly functioned by apolipoproteins and lipid metabolism. Some of the differentially expressed proteins may serve as potential predictor biomarkers along with Aβ42 in plasma for improved CCDS diagnosis.

INSTRUMENT(S): Bruker Daltonics micrOTOF series

ORGANISM(S): Canis Familiaris (dog) (canis Lupus Familiaris)

TISSUE(S): Blood Plasma

SUBMITTER: Sataporn Phochantachinda  

LAB HEAD: Onrapak Reamtong

PROVIDER: PXD023301 | Pride | 2021-09-09

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
Adult10_Rep1.baf Other
Adult10_Rep1.mgf Mgf
Adult10_Rep2.baf Other
Adult10_Rep2.mgf Mgf
Adult10_Rep3.baf Other
Items per page:
1 - 5 of 209
altmetric image

Publications

Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand.

Phochantachinda Sataporn S   Chantong Boonrat B   Reamtong Onrapak O   Chatchaisak Duangthip D  

BMC veterinary research 20210129 1


<h4>Background</h4>Canine cognitive dysfunction syndrome (CCDS) is a progressive neurodegenerative disorder found in senior dogs. Due to the lack of biological markers, CCDS is commonly underdiagnosed. The aim of this study was to identify potential plasma biomarkers using proteomics techniques and to increase our understanding of the pathogenic mechanism of the disease. Plasma amyloid beta 42 (Aβ<sub>42</sub>) has been seen to be a controversial biomarker for CCDS. Proteomics analysis was perfo  ...[more]

Similar Datasets

2023-12-12 | PXD043962 | Pride
2023-04-19 | PXD040454 | Pride
2023-04-19 | PXD040467 | Pride
2022-06-09 | PXD031111 | Pride
2023-07-20 | PXD028438 | Pride
2013-07-05 | E-GEOD-39960 | biostudies-arrayexpress
2023-05-10 | PXD030679 | Pride
2024-08-27 | PXD048033 | Pride
2024-03-15 | PXD043647 | Pride
2018-09-17 | PXD010708 | Pride